Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new medicines that unlock the pharmaceutical potential of the endocannabinoid system to treat diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.